The c.181T > G (p.Cys61Gly) alteration is one of the most common pathogenic BRCA1 founder mutations in Europe (Rebbeck et al., 2018) and a well‐established high‐risk variant (Lindor et al., 2012), whereas the deleterious p.Arg1699Gln mutation is hypomorphic and was suggested to confer intermediate cancer risk (Bouwman et al., 2013; Moghadasi et al., 2018; Spurdle et al., 2012). This evidence concerns the gene BRCA1 and cancer.